Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Artrya collaborates with healthcare facilities that treat chest pain patients to introduce innovative cardiovascular care models powered by artificial intelligence. This approach seamlessly incorporates high-prognostic plaque characteristics into the assessment of coronary artery disease. It enables swift evaluations of chest pain patients in both emergency and primary care environments. Our vision is a society free from the burden of heart attacks. Leveraging AI-generated insights from coronary computed tomography angiography (CCTA), we can rapidly and accurately classify chest pain patients based on the type and quantity of arterial plaque identified. This allows for quick identification of individuals with little to no coronary artery disease, ensuring that no underlying plaque issues could lead to significant cardiac events in the future. By recognizing early indicators of potential heart attacks, we can effectively confirm at-risk patients with acute or unusual chest pain who may require additional investigation and treatment. Ultimately, this advancement aims to enhance patient outcomes and foster a healthier community.

Description

AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Artrya

Country

Australia

Website

www.artrya.com

Vendor Details

Company Name

Lunit

Country

United States

Website

www.lunit.io/en

Product Features

Product Features

Alternatives

Alternatives

Oncora Reviews

Oncora

Oncora Medical
The Galen Platform Reviews

The Galen Platform

Ibex Medical Analytics